OSTX

0.80302.12%
JW

Jutta Wanner

Member of Antibody Drug Conjugate (ADC) Advisory Board

Dr. Jutta Wanner, Ph.D. is Chief Research Officer of Alpha-9 Theranostics, Inc. Dr. Wanner was Senior Vice President of Drug Discovery of Alpha-9 Theranostics, Inc. from March 2023. Dr. Wanner joined the Alpha-9 Theranostics, Inc. in March 2023. Dr. Wanner is Member of Antibody Drug Conjugate (ADC) Advisory Board of OS Therapies Incorporated. Dr. Wanner was Chief Technology Officer of OS Therapies Incorporated until February 14, 2023. Dr. Wanner joins her Tunable Drug Conjugate (Advanced ADC) technology from BlinkBio, where she was Chief Scientific Officer. Before that she was at Roche where she was a co-lead in discovery chemistry. She had been Vice-President & CSO of Coferon, Inc. since January 2018. Dr. Wanner has over 10 years of experience and has led chemistry efforts in areas ranging from kinase to protein-protein interaction targets and from HTS to fragment approaches. She has expertise across multiple therapeutic areas including oncology, inflammation and virology. She served as Director of Chemistry at Coferon, Inc. since joining August 2013. At Hoffmann-La-Roche in Nutley, she served as the Head of the Medicinal Chemistry II Department and as a member of the Leadership team, she co-led Discovery Chemistry. She received her PhD from the University of Kansas and her postdoctoral training at The Scripps Research Institute.

Positions